Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs

Sanofi today joined with the other two insulin juggernauts in the US to lower the price of its best-selling insulin product, Lantus (insulin glargine), by 78% and set a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance. The price shifts will begin in January 2024.